Joseph Scharpf

Joseph Scharpf

Auto-generated profile, based on publicly available information

Joseph Scharpf

Head and Neck Institute, Cleveland Clinic Foundation

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2018 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
RSRick Schneider
Rick Schneider
GRGregory W Randolph
Gregory W Randolph
GDGianlorenzo Dionigi
Gianlorenzo Dionigi
CWChe-Wei Wu
Che-Wei Wu
MBMarcin Barczynski
Marcin Barczynski
HDHenning Dralle
Henning Dralle

6 October 2018 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
CWChe-Wei Wu
Che-Wei Wu
GDGianlorenzo Dionigi
Gianlorenzo Dionigi
MBMarcin Barczynski
Marcin Barczynski
FCFeng‐Yu Chiang
Feng‐Yu Chiang
HDHenning Dralle
Henning Dralle
GRGregory W Randolph
Gregory W Randolph

22 September 2016 in Head & Neck
Verified
Journal Article
Closed access
PDF file
JSJoseph Scharpf
Joseph Scharpf
MTMichael Tuttle
Michael Tuttle
RWRichard Wong
Richard Wong
DRDrew Ridge
Drew Ridge
RSRussell Smith
Russell Smith
GRGregory Randolph
Gregory Randolph

1 April 2023 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
SWShannon S. Wu
Shannon S. Wu
ELEric D. Lamarre
Eric D. Lamarre
AYAnirudh Yalamanchali
Anirudh Yalamanchali
PBPhilip R. Brauer
Philip R. Brauer
HHHanna Hong
Hanna Hong
JSJoseph Scharpf
Joseph Scharpf
Importance: Survival outcomes for anaplastic thyroid cancer (ATC), the most aggressive subtype of thyroid cancers, have remained poor. However, targeted therapies and immunotherapies present new opportunities for treatment of this disease. Evaluations of survival outcomes over time with new multimodal therapies are needed for optimizing treatment plans.Objective: To evaluate the association of treatment strategies and tumor characteristics with overall survival (OS) among patients with ATC.Design, Setting, and Participants: This retrospective case series study evaluated the survival outcomes stratified by treatment strategies and tumor characteristics among patients with ATC treated at a tertiary level academic institution from January 1, 2000, to December 31, 2021. Demographic, tumor, treatment, and outcome characteristics were analyzed. Kaplan-Meier method and log rank test modeled OS by treatment type and tumor characteristics. Data were analyzed in May 2022.Main Outcomes and Measures: Overall survival (OS).Results: The study cohort comprised 97 patients with biopsy-proven ATC (median [range] age at diagnosis, 70 [38-93] years; 60 (62%) female and 85 [88%] White individuals; 59 [61%] never smokers). At ATC diagnosis, 18 (19%) patients had stage IVA, 19 (20%) had stage IVB, and 53 (55%) had stage IVC disease. BRAF status was assessed in 38 patients; 18 (47%) had BRAF-V600E variations and 20 (53%), BRAF wild type. Treatment during clinical course included surgery for 44 (45%) patients; chemotherapy, 41 (43%); definitive or adjuvant radiation therapy, 34 (RT; 35%); and targeted therapy, 28 (29%). Median OS for the total cohort was 6.5 (95% CI, 4.3-10.0) months. Inferior OS was found in patients who did not receive surgery (hazard ratio [HR], 2.12; 95% CI, 1.35-3.34; reference, received surgery), chemotherapy (HR, 3.28; 95% CI, 1.99-5.39; reference, received chemotherapy), and definitive or adjuvant RT (HR, 2.47; 95% CI, 1.52-4.02; reference, received definitive/adjuvant RT). On multivariable analysis, age at diagnosis (HR, 1.03; 95% CI, 1.01-1.06), tumor stage IVC (HR, 2.65; 95% CI, 1.35-5.18), and absence of definitive or adjuvant RT (HR, 1.90; 95% CI, 1.01-3.59) were associated with worse OS.Conclusions and Relevance: This retrospective single-institution study found that lower tumor stage, younger age, and the ability to receive definitive or adjuvant RT were associated with improved OS in patients with ATC.

1 September 2017 in Endocrine Practice
Verified
Journal Article
Closed access
SMSuhael Momin
Suhael Momin
DCDeborah Chute
Deborah Chute
BBBrian Burkey
Brian Burkey
JSJoseph Scharpf
Joseph Scharpf

29 October 2020 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
DBDavid T Broome
David T Broome
RNRobert Naples
Robert Naples
RBRichard Bailey
Richard Bailey
ZTZehra Tekin
Zehra Tekin
MHMoska Hamidi
Moska Hamidi
MSMario Skugor
Mario Skugor
Context: Preoperative imaging is performed routinely to guide surgical management in primary hyperparathyroidism, but the optimal imaging modalities are debated. Objective: Our objectives were to evaluate which imaging modalities are associated with improved cure rate and higher concordance rates with intraoperative findings. A secondary aim was to determine whether additive imaging is associated with higher cure rate. Design, Setting, and Patients: This is a retrospective cohort review of 1485 adult patients during a 14-year period (2004-2017) at an academic tertiary referral center that presented for initial parathyroidectomy for de novo primary hyperparathyroidism. Main Outcome Measures: Surgical cure rate, concordance of imaging with operative findings, and imaging performance. Results: The overall cure rate was 94.1% (95% confidence interval, 0.93-0.95). Cure rate was significantly improved if sestamibi/single-photon emission computed tomography (SPECT) was concordant with operative findings (95.9% vs. 92.5%, P = 0.010). Adding a third imaging modality did not improve cure rate (1 imaging type 91.8% vs. 2 imaging types 94.4% vs. 3 imaging types 87.2%, P = 0.59). Despite having a low number of cases (n = 28), 4-dimensional (4D) CT scan outperformed (higher sensitivity, specificity, positive predictive value, negative predictive value) all imaging modalities in multiglandular disease and double adenomas, and sestamibi/SPECT in single adenomas. Conclusions: Preoperative ultrasound combined with sestamibi/SPECT were associated with the highest cure and concordance rates. If pathology was not found on ultrasound and sestamibi/SPECT, additional imaging did not improve the cure rate or concordance. 4D CT scan outperformed all imaging modalities in multiglandular disease and double adenomas, and sestamibi/SPECT in single adenomas, but these findings were underpowered.